Mizuho Securities Maintains a Hold Rating on Adaptimmune Therapeutics (ADAP)
In a report released today, Mara Goldstein from Mizuho Securities maintained a Hold rating on Adaptimmune Therapeutics (ADAP), with a price target of $3.00. The company’s shares closed last Friday at $11.91.
According to TipRanks.com, Goldstein is a 1-star analyst with an average return of -0.5% and a 34.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Corvus Pharmaceuticals, and Autolus Therapeutics.
Adaptimmune Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.00.
See today’s analyst top recommended stocks >>
Based on Adaptimmune Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $761K and GAAP net loss of $28.17 million. In comparison, last year the company had a GAAP net loss of $27.41 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.